World Immunotherapy Congress - Agenda Day 3

 

World Immunotherapy Congress 2018, Day 3

08:00 Registration Opens

Keynote plenary - World leading research

09:00

Chair's opening remarks

09:05

Passive immunotherapy of viral infections: ‘super-antibodies’ enter the fray

09:30

T cell immunity in human cancer

09:55

Pharmacodynamic biomarker identification

Heinz Läubli
10:20

Targeting of the sialoglycan-SAMP/Siglec pathway in vitro and in vivo resulted in increased anti-cancer immunity

  • Changes of glycans in the tumor microenvironment
  • Upregulation of sialoglycans increase density of ligands for Siglec receptor
  • Siglec receptors are new immune checkpoints upregulated on tumor-infiltrating T cells
  • Siglec-sialoglycan interactions can be targeted to improve anti-cancer immunity

10:45 Networking Break

Cancer vaccines

Safety and efficacy

Chaired by TBC

Chaired by TBC

Cancer vaccines
11:45

PDC*line Pharma semi-allogeneic cancer vaccine: how abortive allogeneic immune response can prime and boost the induction of specific anti-tumor T cells

  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • The technology can be applied for any type of cancer
Safety and efficacy
11:45

Tolerogenic nanoparticles to mitigate immunogenicity and improve the efficacy of immunotoxins for cancer therapy

  • The development of anti-drug antibodies (ADAs) can compromise the efficacy and safety of biologic therapies
  • Recombinant immunotoxins are potent but highly immunogenic anti-cancer agents
  • We have partnered with the National Cancer Institute to demonstrate that synthetic vaccine particles nanoparticles containing rapamycin (SVP-Rapamycin) effectively mitigate ADAs against LMB-100, a mesothelin-targeted immunotoxin, and enables robust anti-tumor responses in preclinical models
  • The combination of LMB-100 and SVP-Rapamycin is currently in clinical trials for the treatment of patients with mesothelioma
Cancer vaccines
12:05

Cell penetrating peptides and TLR peptide agonist: the swiss army knife of cancer vaccines

  • Therapeutics cancer vaccines
  • Chimeric proteins
  • Multi-antigenic T cells immunity responsive
Safety and efficacy
12:05

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Cancer vaccines
12:25

Reserved for Supporting Partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Cancer vaccines
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Safety and efficacy
12:45

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Cancer vaccines
13:05

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297
Safety and efficacy
13:05

Reserved for supporting partner

If you are interested in being involved, please contact Derek Cavanagh at derek.cavanagh@terrapinn.com or +44 207 092 1297

13:25 Networking Lunch

Closing plenary – biomarkers and precision medicine for immunotherapy

Chaired by TBC

Serafino Pantano
14:25

Patient selection strategies for making precision medicine a reality in immuno-oncology

Thomas Hach
14:45

The future of precision medicine

  • Oncology and genomics: halfway there
  • Immunology and more Omics: we’re just starting
  • The future: complexity simplified, research put into practice, digital put into action
15:05

Discovery, development and commercialization of personalized cellular immunotherapies to improve outcomes in organ transplant recipients

15:25

Response and resistance in CAR-T therapy

15:45

Chairman's closing remarks

15:55

Closing remarks from Terrapinn

16:00 End of Congress

last published: 20/Jul/18 13:45 GMT

 

Mark Your Calendars Now!
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October 

Sign Up for Event Updates